ICER and BMS continue to differ on mavacamten stance

17 November 2021

The USA's Institute for Clinical and Economic Review (ICER) has published a Final Evidence Report assessing the comparative clinical effectiveness and value of mavacamten, a drug being developed for hypertrophic cardiomyopathy (HCM).

Mavacamten was acquired in last year’s $13.1 billion buy of MyoKardia by Bristol Myers Squibb (NYSE: BMY), and the US pharma major has already objected to the ICER’s assessment of the drug’s value.

"Additional safety data are needed"In a report published in October 2021, the ICER said that a fair price for the drug in the USA would be between $12,000 and $15,000 per year, according to its estimates. This is significantly lower than the $75,000 annual price that some industry analysts have forecasted.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK